LOGIN  |  REGISTER
Terns Pharmaceuticals
Amneal Pharmaceuticals

Qrons Announces Engagement of Israeli Intellectual Property Law Firm IPK to Develop Roadmap for Its New Product Line

January 17, 2023 | Last Trade: US$0.16 0.00 0.00

NEW YORK, NY / ACCESSWIRE / January 17, 2023 / Qrons Inc. (OTCQB:QRON) announced today that it had engaged with the intellectual property law firm IPK, an Israeli firm with unique expertise in medical-related intellectual property development and protection. Working closely with IPK will enable Qrons to tailor an intellectual property strategy and roadmap addressing its new product line. Qrons has previously worked with IPK founder Dr. Paul Kaye.

This follows the formation of a collaboration between Qrons and scientists at one of the largest public research universities in Israel, who have created a family of compounds with promising medical applications. This collaboration is directed toward further investigating these compounds and developing them into therapeutic products and treatments, including synergies with Qrons' QS200™ product candidate for treatment of diffused axonal injuries (also commonly referred to as concussions) which accounts for approximately 89% of Traumatic Brain Injuries ("TBIs").

Jonah Meer, CEO commented, "We have chosen to work with IPK as Dr. Kaye has worked with Qrons for the last several years and proven himself to be an important value added as we build our intellectual property portfolio. He has assembled a team at the IPK law firm that has the scientific knowledge and bandwidth to advance our IP."

Dr. Paul Kaye, founder of IPK stated "We have enjoyed working with Qrons for several years, and are honored and excited to continue to accompany the team on its journey to create and develop potentially life-changing technologies."

About Qrons Inc.

Headquartered in New York City, with research centered in Israel, Qrons (www.qrons.com) is an innovative biotechnology company dedicated to developing biotech products, treatments and technologies to combat neuronal diseases an enormous social and economic burden on society. Qrons' approach is to seek to engage in strategic arrangements with companies and institutions that are developing breakthrough technologies in the fields of artificial intelligence, machine learning, molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases. Our search is focused on researchers based in Israel, a country which is world-renowned for biotech innovations.

About IPK

IPK (www.ipk.co.il) is an intellectual property law firm that works very closely with its clients not just on their technology but on the commercials as well. They bring new ideas to intellectual property law. With their top-notch practitioners, they obtain the strong protection that their clients' ideas deserve.

Contact:

Qrons Inc.
Jonah Meer
Chief Executive Officer
212-945-2080

Chimerix

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB